6CM
CRBP icon

683 Capital Management’s Corbus Pharmaceuticals CRBP Stock Holding History

683 Capital Management’s Portfolio CRBP Stock Details CRBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$803K Hold
85,543
– – 0.04% 147
2025
Q4 		$696K Buy
+85,543
New +$1.06M 0.03% 171

Other funds holding CRBP

CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
DP
Diadema Partners Morristown, New Jersey $588M AUM 182.75% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

683 Capital Management's CRBP Position: Q1 2026 in Review

683 Capital Management held its Corbus Pharmaceuticals (CRBP) position steady in Q1 2026 at 85,543 shares worth $803K. The position accounts for 0.04% of the portfolio, ranked #147.

683 Capital Management first reported a position in CRBP in Q4 2025 and has held it in 2 quarters since. 107 funds tracked by Wall St. Rank hold CRBP as of Q1 2026.

  • 683 Capital Management held 85,543 shares of Corbus Pharmaceuticals worth $803K as of Q1 2026.
  • 683 Capital Management left its Corbus Pharmaceuticals share count unchanged in Q1 2026.
  • Corbus Pharmaceuticals made up 0.04% of 683 Capital Management's portfolio in Q1 2026, its #147 holding.
  • 683 Capital Management first reported a position in Corbus Pharmaceuticals in Q4 2025 and has held it in 2 quarters since.
  • 107 funds tracked by Wall St. Rank held Corbus Pharmaceuticals as of Q1 2026.

Based on 683 Capital Management's 13F filing for Q1 2026, filed 15 May 2026.